Primary and secondary ethical issues arising from the introduction of recombinant factor VIII: "primum non nocere," but what next?
McDonald
M
M
Centre for Applied Ethics, University of British Columbia, Vancouver, Canada.
D000163:Acquired Immunodeficiency Syndrome / Q000635:transmission; D026686:Beneficence; D026689:Ethical Analysis; D004992:Ethics, Medical; D005169:Factor VIII / Q000009:adverse effects / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D028681:Moral Obligations; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012935:Social Justice
D011994:Recombinant Proteins; D005169:Factor VIII